Get notified when IMMX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states it may not be able to continue as a going concern if it cannot raise sufficient capital.
Immix Biopharma prices $150M primary offering at $8.94/share; net proceeds $140.7M
Filed May 21, 2026 · ~1 min read
Key Changes
-
high
Immix Biopharma is selling 16,778,524 new shares at $8.94 per share, raising $150.0M gross and $140.7M net for the company.
The Offering verify on EDGAR → -
high
Net proceeds will fund NXC-201 development, working capital, and general corporate purposes.
Use of Proceeds verify on EDGAR → -
high
New investors face immediate dilution of $5.59 per share: pro forma net tangible book value is $3.35 vs. the $8.94 offer price.
Dilution verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PATH 10-Q) is open in full — no account needed.
Partner
Trade IMMX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify